By Bowsea Editorial Desk · Editorial Team, Bowsea · Published 2026-05-25
Post-Brexit MHRA reforms aimed at faster approvals for innovative therapies are increasing demand for regulatory affairs and pharmacovigilance professionals at UK-domiciled biotechs and CROs.
MHRA has positioned itself as a faster-moving regulator than the EMA on innovative therapies (cell + gene, AI-enabled diagnostics). For UK-domiciled biotechs and contract research organisations, that's translated into a real hiring need: regulatory affairs professionals who can navigate the new pathways and pharmacovigilance staff who can stand up post-market surveillance for novel modalities. For career movers from clinical, scientific, or quality-assurance roles, regulatory affairs is one of the cleanest pivots in life sciences — the qualification (TOPRA's RAC credential) is well-defined, a